GHK-Cu

GHK-Cu is a copper-coordinating tripeptide whose structural framework — Gly-His-Lys with a square-planar Cu(II) coordination geometry — provides the basis for its biochemical interaction profile in the literature. The histidine imidazole nitrogen, the N-terminal amine, and a deprotonated peptide nitrogen together coordinate the copper ion, producing a stable complex documented across copper-peptide chemistry investigations. Pharmacokinetic descriptors documented in published work include rapid copper exchange with serum carriers and a short systemic half-life of the intact complex under standard parenteral paradigms. Interaction profile in published work spans extracellular-matrix-protein gene-expression modulation in fibroblast cultures, antioxidant-pathway engagement, and mitochondrial-function markers in keratinocyte-model assays. All activity descriptors here are framed as documented in published research. Structural confirmation is established by mass spectrometry and HPLC purity validation on each Certificate of Analysis.

Experimental domains documented in the published literature include copper-peptide coordination chemistry, in-vitro fibroblast collagen and elastin gene-expression studies, keratinocyte signaling investigations, antioxidant-pathway assays, mitochondrial-function research in skin-cell models, and comparative work alongside other copper-binding peptides. Investigators have also characterized GHK-Cu in studies of plasma copper transport and in screening assays for cell-culture media supplementation effects on extracellular-matrix synthesis. Use in laboratory research extends to mechanism-elucidation paradigms where the molecule serves as a probe for copper-mediated cellular signaling rather than as a defined intervention. The reference standard is supplied for these and equivalent in-vitro experimental contexts only, with no associated guidance for human, clinical, cosmetic, or veterinary application. Researchers should consult primary literature for context-specific protocols.

Each lot is characterized by reverse-phase HPLC for chromatographic purity and by mass spectrometry for molecular-ion confirmation of the GHK tripeptide and copper-complex composition. Purity is reported as an HPLC-area percentage on the Certificate of Analysis distributed with every lot, alongside copper content quantification by atomic-absorption or ICP-MS analysis where included in the release specification. Peptide content is determined by amino-acid analysis following the analytical method specified on the COA. Residual solvent and water content are reported categorically when these parameters are part of the lot's release specification. The COA records the lot identifier, manufacturing date, and analytical method versions used, providing a traceable provenance chain from synthesis through release. Researchers requiring batch-level analytical detail should reference the COA distributed with the supplied material.

For laboratory storage, the lyophilized reference standard should be held at −20°C in its sealed, light-protected container until ready for analytical use. Light protection is important for copper-coordinated peptide complexes — exposure to UV or strong visible light can perturb the copper-coordination geometry over time. Allow vials to equilibrate to ambient temperature before opening to avoid moisture condensation on the lyophile. Reconstitution for in-vitro experimental use is typically performed in a researcher-selected buffer compatible with the downstream assay; once reconstituted, store the working solution at 2–8°C, protected from light, and characterize copper-complex stability in the relevant buffer prior to extended storage. Avoid repeated freeze-thaw cycles. These handling parameters reflect general best-practice for copper-peptide reference standards and do not constitute preparation guidance for human, cosmetic, or veterinary application.